(Total Views: 356)
Posted On: 10/09/2019 2:20:13 PM
Post# of 148870
Re: Evil Rabbit #9379
I, for the life of me, cannot figure out why NP and MM continue to try to tap the high net-worth, individual investor well. All the $210M they have raised has been via this route. Why not get an institutional investor who specializes in pharma?
NP regularly references the investment banks that want him to raise money though them -- and he rightfully disregards those offers. They will undoubtedly be significantly in the bank's favor. (That being said, we would have been better off having one of those financings 12-24 months ago vs. the steady decline via the micro raises which have resulted in substantially more dilution than even one of those i-bank raises).
But aside from i-banks, who are not investors, they are just transnational risk managers -- a pharma: VC, private equity, or hedge fund would be a perfect fit for our situation. And they would likely invest at a premium to our current SP (vs. the current discounted ATM raises).
IMO, this is where strong management makes a world of difference (how to raise money and "play the game"
. Don't forget that ThaiMed had over $1.6B market cap long before the stage we are currently in. And the major differences were: 1) IZ is an inferior product; but 2) they had raised traditional VC and IPO money and had money in the bank; and 3) they had signed their go-to-market sales partner.
Hopefully, the dam will finally break when we announce our go-to-market sales partner.
NP regularly references the investment banks that want him to raise money though them -- and he rightfully disregards those offers. They will undoubtedly be significantly in the bank's favor. (That being said, we would have been better off having one of those financings 12-24 months ago vs. the steady decline via the micro raises which have resulted in substantially more dilution than even one of those i-bank raises).
But aside from i-banks, who are not investors, they are just transnational risk managers -- a pharma: VC, private equity, or hedge fund would be a perfect fit for our situation. And they would likely invest at a premium to our current SP (vs. the current discounted ATM raises).
IMO, this is where strong management makes a world of difference (how to raise money and "play the game"
. Don't forget that ThaiMed had over $1.6B market cap long before the stage we are currently in. And the major differences were: 1) IZ is an inferior product; but 2) they had raised traditional VC and IPO money and had money in the bank; and 3) they had signed their go-to-market sales partner. Hopefully, the dam will finally break when we announce our go-to-market sales partner.
(4)
(0)Scroll down for more posts ▼
